COAG — Hemab Therapeutics Holdings, Inc.
—
Nasdaq ·
Health Care ·
Biotechnology ·
CIK 2114044 ·
Last close
$34.74
Market Cap
$1.62B
52W High
$55.42
52W Low
$23.00
ADV30
497,073
Next earnings
2026-11-16
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Jun 2026 | 0 | — | -26,079,000 | -24,150,000 | 467,781,000 | 237,366,000 | 13,510,000 |
| Mar 2026 | — | — | — | — | — | — | — |
| Jun 2025 | 0 | — | -16,057,000 | -12,209,000 | — | — | — |
| Mar 2025 | 0 | — | -16,560,000 | -15,306,000 | — | — | — |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-34,617,000
Investing CF
$-21,841,000
Financing CF
$-489,000
CapEx
$-128,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-16.69
As of
2026-08-16
Balance + Analyst (yfinance extras)
Retained Earnings
$-204,545,000
Inventory
—
Receivables
$1,430,000
ST Investments
$113,671,000
EBIT TTM
$-40,172,000
Pretax Income TTM
$-38,171,000
Interest Exp TTM
—
Analysts
5
Annual Trend (SEC EDGAR, last 2y)
Revenues vs Net Income (last 2y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 0 | -70,119,000 | -63,913,000 | 194,783,000 | 371,418,000 | -176,635,000 | -61,475,000 |
| Dec 2024 | 0 | -50,383,000 | -48,707,000 | 96,278,000 | 211,551,000 | -115,273,000 | -45,592,000 |
TTM Snapshot
Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
—
Forward EPS
$-2.54
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| IMCR | Immunocore Holdings plc | $1.58B | $30.72 | — |
| TSHA | Taysha Gene Therapies, Inc. | $1.52B | $4.67 | — |
| NVAX | NOVAVAX INC | $1.75B | $10.63 | — |
| INBX | Inhibrx Biosciences, Inc. | $1.47B | $99.61 | — |
| VIR | Vir Biotechnology, Inc. | $1.80B | $10.66 | — |
News headlines (Yahoo Finance, 1h cache)
Hemab Therapeutics Strengthens Board of Directors with Appointment of Keli Walbert
2026-09-24 20:01 · Yahoo
Hemab Therapeutics Announces First Participant Dosed in Phase 1 Clinical Trial of HMB-003, an Investigational Therapy for the Management of Heavy Menstrual Bleeding
2026-09-17 12:00 · Yahoo
Hemab Therapeutics Reports First Quarter 2026 Financial Results
2026-05-21 11:00 · Yahoo
Hemab Therapeutics Announces Closing of Upsized Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares
2026-05-04 20:01 · Yahoo
Hemab Therapeutics Announces Pricing of Upsized Initial Public Offering
2026-04-30 22:55 · Yahoo
Hemab Therapeutics Presents Clinical and Preclinical Data from Sutacimig in Glanzmann Thrombasthenia and Factor VII Deficiency at the ISTH 2026 Congress
2026-07-14 11:45 · Yahoo
Hemab Therapeutics Presents New Clinical Data from HMB-002 in Von Willebrand Disease and Introduces HMB-003 for Heavy Menstrual Bleeding at the ISTH 2026 Congress
2026-07-12 10:28 · Yahoo
Hemab Therapeutics Details Post-IPO Pipeline Push, Sutacimig Phase III Plans
2026-06-09 03:03 · Yahoo
Hemab Therapeutics to Participate in the 2026 Jefferies Global Healthcare Conference
2026-05-27 12:00 · Yahoo
Hemab Therapeutics IPO Debut Puts COAG And Pipeline Risks In Focus
2026-05-03 07:07 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.